Halozyme Therapeutics HALO Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's cash provided by (used in) operating activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's cash provided by (used in) operating activity, including discontinued operation?
- Halozyme Therapeutics (HALO) reported cash provided by (used in) operating activity, including discontinued operation of $180.08M in Q1 2026.
- How has Halozyme Therapeutics's cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
- Halozyme Therapeutics's cash provided by (used in) operating activity, including discontinued operation increased by 16.8% year-over-year, from $154.22M to $180.08M.
- What is the long-term trend for Halozyme Therapeutics's cash provided by (used in) operating activity, including discontinued operation?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's cash provided by (used in) operating activity, including discontinued operation has grown at a 21.5% compound annual growth rate (CAGR), from $299.44M to $651.56M.
- What does cash provided by (used in) operating activity, including discontinued operation mean?
- Measures the cash generated from the company's core business operations, excluding financing and investing activities. It reflects the ability of the company to convert revenue into actual cash flow after accounting for changes in working capital.